Expression of the complement alternative pathway by human myoblasts in vitro: Biosynthesis of C3, factor B, factor H and factor I
- 1 December 1995
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 25 (12) , 3460-3466
- https://doi.org/10.1002/eji.1830251238
Abstract
In this study, we demonstrate expression in vitro of complement alternative pathway components C3, factor B, factor H and factor I by normal human myoblasts and human rhabdomyosarcoma cell lines CRL1558 and HTB153. Proteins in culture supernatants were detected by Western (protein) blot analysis and biosynthetic labeling followed by immunoprecipitation experiments, and quantified by ELISA. Newly secreted proteins were structurally and functionally similar to their serum counterparts. An additional polypeptide of 43 kDa with factor H immunoreactivity was detected, which could correspond to the N-terminal truncated form found in plasma. Protein expression was correlated with mRNA expression by reverse transcriptase-polymerase chain reaction analysis. The major proteins of complement alternative pathway C3, factor B and factor H were produced constitutively by skeletal muscle cells at a rate of 50 to 150 ng/106 cells/ml and factor I was expressed 20 ng/106 cells/ml. These syntheses in vitro were regulated by inflammatory cytokines. Interferon-γ significantly upregulated C3, factor B and factor H expression, but had no effect on factor I production. Interleukin-1β strongly enhanced C3 and factor B production and had a weak enhancing or no effect on factor I and factor H secretion. Human myoblast cell lines constitute an interesting model to analyze complement biosynthesis by human skeletal muscle cells. Local complement expression by skeletal muscle in vivo may be implicated in some muscular inflammatory or pathological processes.Keywords
This publication has 15 references indexed in Scilit:
- The immunobiology of muscleImmunology Today, 1994
- Myasthenia gravisNeurology, 1993
- Activation of the alternative complement pathway and production of Factor H by skeletal myotubesJournal of Neuroimmunology, 1993
- Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end‐plate in minimal myasthenia gravisNeurology, 1989
- Human complement factor H: An additional gene product of 43kDa isolated from human plasma shows cofactor activity for the cleavage of the third component of complementEuropean Journal of Immunology, 1989
- Immunocytochemical localisation of complement components C8 and C9 in human diseased muscle the role of complement in muscle fibre damageJournal of the Neurological Sciences, 1987
- Immunoblotting analysis of the peptide chain structure of the physiological breakdown products of the third component of human complementElectrophoresis, 1986
- Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.Journal of Neurology, Neurosurgery & Psychiatry, 1985
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979
- Antibody to acetylcholine receptor in myasthenia gravisNeurology, 1976